Multifunctional nanoparticles for use in theranostic applications

Theranostics is a promising field that combines therapeutics and diagnostics into single multifunctional formulations. This field is driven by advancements in nanoparticle systems capable of providing the necessary functionalities. By utilizing these powerful nanomedicines, the concept of personalized medicine can be realized by tailoring treatment strategies to the individual. This review gives a brief overview of the components of a theranostic system and the challenges that designing truly multifunctional nanoparticles present. Considerations when choosing a class of nanoparticle include the size, shape, charge, and surface chemistry, while classes of nanoparticles discussed are polymers, liposomes, dendrimers, and polymeric micelles. Targeting to disease states can be achieved either through passive or active targeting which uses specific ligands to target receptors that are overexpressed in tumors and common targeting elements are presented. To image the interactions with disease states, contrast agents are included in the nanoparticle formulation. Imaging options include optical imaging techniques, computed tomography, nuclear based, and magnetic resonance imaging. The interplay between all of these components needs to be carefully considered when designing a theranostic system.

[1]  G. Baldwin,et al.  Gastrin-releasing peptide and cancer. , 2006, Biochimica et biophysica acta.

[2]  Jan Grimm,et al.  An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles , 2006, Nature materials.

[3]  T. Koji,et al.  Doxorubicin‐induced DNA intercalation and scavenging by nuclear glutathione S‐transferase π , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[5]  D. Discher,et al.  Shape effects of filaments versus spherical particles in flow and drug delivery. , 2007, Nature nanotechnology.

[6]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[7]  Ezequiel Bernabeu,et al.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer. , 2012, Biochimica et biophysica acta.

[8]  B. Liu,et al.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  C. Ehrhardt,et al.  In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  T. Park,et al.  siRNA delivery systems for cancer treatment. , 2009, Advanced drug delivery reviews.

[11]  H. Maeda,et al.  The EPR Effect and Polymeric Drugs: A Paradigm Shift for Cancer Chemotherapy in the 21st Century , 2005 .

[12]  S. Bhatia,et al.  Probing the Cytotoxicity Of Semiconductor Quantum Dots. , 2004, Nano letters.

[13]  Domenico Coppola,et al.  MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer* , 2008, Journal of Biological Chemistry.

[14]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[15]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[16]  D. Neri,et al.  The use of phage display for the development of tumour targeting agents. , 2000, Advanced drug delivery reviews.

[17]  M. Schwaiger,et al.  Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  Rongsheng E. Wang,et al.  Development of NGR peptide-based agents for tumor imaging. , 2011, American journal of nuclear medicine and molecular imaging.

[19]  Tina Hernandez-Boussard,et al.  Doxorubicin pathways: pharmacodynamics and adverse effects , 2011, Pharmacogenetics and genomics.

[20]  P. Keegan,et al.  FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). , 2007, The oncologist.

[21]  Mary E Napier,et al.  More effective nanomedicines through particle design. , 2011, Small.

[22]  Yasunori Fujita,et al.  Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. , 2008, Biochemical and biophysical research communications.

[23]  Subra Suresh,et al.  Size‐Dependent Endocytosis of Nanoparticles , 2009, Advanced materials.

[24]  H. Ueno,et al.  Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin , 2004, British Journal of Cancer.

[25]  H. Hong,et al.  In Vivo Tumor Targeting and Drug Delivery with Mesoporous Silica Nanoparticles , 2013 .

[26]  Kwangmeyung Kim,et al.  Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. , 2012, Biomaterials.

[27]  Tejraj M Aminabhavi,et al.  Recent advances on chitosan-based micro- and nanoparticles in drug delivery. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[28]  J. Bacri,et al.  Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. , 2003, Biomaterials.

[29]  Jinho Park,et al.  Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy , 2012, Theranostics.

[30]  A. R. Kulkarni,et al.  Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Pedro M. Valencia,et al.  Targeted Polymeric Therapeutic Nanoparticles: Design, Development and Clinical Translation , 2012 .

[32]  M J Hawkins,et al.  Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  Efstathios Karathanasis,et al.  Targeted nanotechnology for cancer imaging. , 2014, Advanced drug delivery reviews.

[34]  C. Takimoto,et al.  Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors. , 2007 .

[35]  Robert Langer,et al.  Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. , 2007, Nano letters.

[36]  Mark E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[37]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[38]  K. Kataoka,et al.  NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel , 2005, British Journal of Cancer.

[39]  Dong Soo Lee,et al.  Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125. , 2011, Small.

[40]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[41]  R. Berges Eligard®: Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability , 2005 .

[42]  S. Sahoo,et al.  PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. , 2011, Advanced drug delivery reviews.

[43]  Theresa M Reineke,et al.  Theranostics: combining imaging and therapy. , 2011, Bioconjugate chemistry.

[44]  E. Nagore,et al.  Antineoplastic Therapy—Induced Palmar Plantar Erythrodysesthesia (‘Hand-Foot’) Syndrome , 2000, American journal of clinical dermatology.

[45]  J Verweij,et al.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[46]  Y. Matsumura Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. , 2011, Advanced drug delivery reviews.

[47]  Philip S Low,et al.  Folate receptor-mediated drug targeting: from therapeutics to diagnostics. , 2005, Journal of pharmaceutical sciences.

[48]  Y. Maitani,et al.  Functional coating of liposomes using a folate– polymer conjugate to target folate receptors , 2012, International journal of nanomedicine.

[49]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[50]  Igor L. Medintz,et al.  Quantum dot bioconjugates for imaging, labelling and sensing , 2005, Nature materials.

[51]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[52]  M. Kalia,et al.  Personalized oncology: recent advances and future challenges. , 2013, Metabolism: clinical and experimental.

[53]  C. Lok,et al.  The transferrin receptor: role in health and disease. , 1999, The international journal of biochemistry & cell biology.

[54]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[55]  Samir Mitragotri,et al.  Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[56]  Norased Nasongkla,et al.  Functionalized Micellar Systems for Cancer Targeted Drug Delivery , 2007, Pharmaceutical Research.

[57]  Sarah Hitch,et al.  THE CHRONOLOGY OF EARLY EPIC , 2014, The Classical Review.

[58]  Seungpyo Hong,et al.  The Binding Avidity of a Nanoparticle-based Multivalent Targeted Drug Delivery Platform , 2022 .

[59]  Menachem Motiei,et al.  Nanoparticles as computed tomography contrast agents: current status and future perspectives. , 2012, Nanomedicine.

[60]  V. Muzykantov,et al.  Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities , 2012, Science.

[61]  Xianglong Hu,et al.  Multifunctional pH-disintegrable micellar nanoparticles of asymmetrically functionalized β-cyclodextrin-based star copolymer covalently conjugated with doxorubicin and DOTA-Gd moieties. , 2012, Biomaterials.

[62]  S S Gambhir,et al.  Molecular imaging: current status and emerging strategies. , 2010, Clinical radiology.

[63]  Pat Zanzonico,et al.  Principles of Nuclear Medicine Imaging: Planar, SPECT, PET, Multi-modality, and Autoradiography Systems , 2012, Radiation research.

[64]  Francesco Stellacci,et al.  Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.

[65]  D. Simberg,et al.  Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems , 2011, Expert opinion on drug delivery.

[66]  Mingwu Shen,et al.  Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. , 2013, Biomaterials.

[67]  S. Sahoo,et al.  Nanotech approaches to drug delivery and imaging. , 2003, Drug discovery today.

[68]  Gaurav Sahay,et al.  Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[69]  Indu Bala,et al.  PLGA nanoparticles in drug delivery: the state of the art. , 2004, Critical reviews in therapeutic drug carrier systems.

[70]  H. Shan,et al.  An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma , 2012, International journal of nanomedicine.

[71]  É. Boisselier,et al.  Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine. , 2010, Chemical reviews.

[72]  P. Low,et al.  Folate-targeted therapeutic and imaging agents for cancer. , 2009, Current opinion in chemical biology.

[73]  T. Yen,et al.  Multifunctional hollow nanoparticles based on graft-diblock copolymers for doxorubicin delivery. , 2011, Biomaterials.

[74]  S. Sahoo,et al.  Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer , 2004, International journal of cancer.

[75]  A. Bjourson,et al.  Diagnostic, Prognostic and Theranostic Genetic Biomarkers for Rheumatoid Arthritis , 2013 .

[76]  D. Tien,et al.  Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model. , 2013, Bioorganic & medicinal chemistry letters.

[77]  C. Fraser,et al.  Development and preclinical evaluation of SEL-068, a novel targeted Synthetic Vaccine Particle (tSVP™) for smoking cessation and relapse prevention that generates high titers of antibodies against nicotine (75.11) , 2012, The Journal of Immunology.

[78]  Ying Liu,et al.  Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. , 2011, Small.

[79]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[80]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[81]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[82]  Xue-Long Sun,et al.  Chemically-selective surface glyco-functionalization of liposomes through Staudinger ligation. , 2009, Chemical communications.

[83]  R. Tsien,et al.  Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases , 2010, Proceedings of the National Academy of Sciences.

[84]  Mingwu Shen,et al.  Targeted cancer theranostics using alpha-tocopheryl succinate-conjugated multifunctional dendrimer-entrapped gold nanoparticles. , 2014, Biomaterials.

[85]  R. Roesler,et al.  Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  Stan W. Casteel,et al.  Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity , 2010, Proceedings of the National Academy of Sciences.

[87]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[88]  Shan Jiang,et al.  Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. , 2007, Biomaterials.

[89]  J. Arias,et al.  Drug targeting strategies in cancer treatment: an overview. , 2011, Mini reviews in medicinal chemistry.

[90]  Kostas Kostarelos,et al.  Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. , 2011, Accounts of chemical research.

[91]  Donghoon Lee,et al.  Optical and MRI multifunctional nanoprobe for targeting gliomas. , 2005, Nano letters.

[92]  P. Choyke,et al.  Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target? , 2013, Theranostics.

[93]  Y. Jeong,et al.  A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. , 2010, ACS nano.

[94]  Z. Fayad,et al.  Molecular imaging of tumor angiogenesis using αvβ3-integrin targeted multimodal quantum dots , 2008, Angiogenesis.

[95]  P. Nygren,et al.  Alternative binding proteins: Affibody binding proteins developed from a small three‐helix bundle scaffold , 2008, The FEBS journal.

[96]  Marilena Loizidou,et al.  Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. , 2009, Trends in pharmacological sciences.

[97]  Y. Yarden The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[98]  M Ferrari,et al.  Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[99]  Beom Suk Lee,et al.  Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. , 2012, Biomaterials.

[100]  Gert Storm,et al.  Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release , 2010, Pharmaceutical Research.

[101]  Stephanie E. A. Gratton,et al.  The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.

[102]  Antonina Rait,et al.  Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[103]  Xiaoyuan Chen,et al.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[104]  Tae-You Kim,et al.  Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies , 2004, Clinical Cancer Research.

[105]  E. Moase,et al.  Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer , 2008, Journal of drug targeting.

[106]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[107]  R. Schiffelers,et al.  ICS-283: a system for targeted intravenous delivery of siRNA , 2006, Expert opinion on drug delivery.

[108]  Probal Banerjee,et al.  Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment. , 2010, Biomaterials.

[109]  H. Maeda Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting , 2012, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[110]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[111]  V. Torchilin,et al.  Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.

[112]  L. Kaminskas,et al.  Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. , 2011, Nanomedicine.

[113]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[114]  Jonathan D. Ashley,et al.  Ligand-targeted liposome design: challenges and fundamental considerations. , 2014, Trends in biotechnology.

[115]  D. Kerr,et al.  Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer , 2004, British Journal of Cancer.

[116]  Craig J Hawker,et al.  Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer. , 2013, Bioconjugate chemistry.

[117]  Hongzhe Sun,et al.  Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway , 2002, Pharmacological Reviews.

[118]  S. Ferrari,et al.  Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma , 2007, Anti-cancer drugs.

[119]  A. S. Moses,et al.  Imaging and drug delivery using theranostic nanoparticles. , 2010, Advanced drug delivery reviews.

[120]  J. Reubi Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.

[121]  Michael J Welch,et al.  Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications. , 2012, Bioconjugate chemistry.

[122]  B. Cheson,et al.  Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.

[123]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[124]  A. M. Rush,et al.  X-ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles. , 2011, Angewandte Chemie.

[125]  G. Hsiue,et al.  Multifunctional Micelles for Cancer Cell Targeting, Distribution Imaging, and Anticancer Drug Delivery , 2007 .

[126]  Y. Barenholz Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[127]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[128]  G. Calin,et al.  Non‐coding RNAs as theranostics in human cancers , 2012, Journal of cellular biochemistry.

[129]  Kerry K. Karukstis,et al.  Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.

[130]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[131]  Nicholas J Long,et al.  'Two is better than one'--probes for dual-modality molecular imaging. , 2009, Chemical communications.

[132]  I. Kwon,et al.  Theranostic nanoparticles for future personalized medicine. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[133]  J. Minna,et al.  MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. , 2010, Molecular pharmaceutics.

[134]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[135]  R. Niu,et al.  Folate-targeting magnetic core-shell nanocarriers for selective drug release and imaging. , 2012, International journal of pharmaceutics.

[136]  K. Landfester,et al.  Uptake mechanism of oppositely charged fluorescent nanoparticles in HeLa cells. , 2008, Macromolecular bioscience.

[137]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[138]  Jean-Pierre Benoit,et al.  Parameters influencing the stealthiness of colloidal drug delivery systems. , 2006, Biomaterials.

[139]  Clara L Santos-Cuevas,et al.  Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression. , 2011, Bioconjugate chemistry.

[140]  Y. Bae,et al.  A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle. , 2014, Biomaterials.

[141]  Kazuo Maruyama,et al.  Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. , 2011, Advanced drug delivery reviews.

[142]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[143]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[144]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[145]  S. Swanson,et al.  Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement , 2008, International journal of nanomedicine.

[146]  Kangseok Lee,et al.  Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles. , 2011, Journal of biotechnology.

[147]  D. Faulds,et al.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. , 1994, Drugs.

[148]  Gil Y. Melmed,et al.  Certolizumab pegol , 2022, Nature Reviews Drug Discovery.

[149]  Horst Kessler,et al.  Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting , 1999 .

[150]  Y. Shimada,et al.  Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[151]  Z. Hua Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .

[152]  M. Ross,et al.  Daunoxome® Treatment of Solid Tumors: Preclinical and Clinical Investigations , 1994 .

[153]  E. Olson,et al.  Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. , 2010, Cancer cell.

[154]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[155]  Subhra Mohapatra,et al.  Multifunctional Chitosan Magnetic-Graphene (CMG) Nanoparticles: a Theranostic Platform for Tumor-targeted Co-delivery of Drugs, Genes and MRI Contrast Agents. , 2013, Journal of materials chemistry. B.

[156]  Srikanth K. Iyer,et al.  Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. , 2011, The Journal of clinical investigation.

[157]  Cao Xie,et al.  Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[158]  Werner Jaschke,et al.  Molecular imaging with nanoparticles: giant roles for dwarf actors , 2008, Histochemistry and Cell Biology.

[159]  Robert Langer,et al.  Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.

[160]  Horst Kessler,et al.  RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. , 2003, Biomaterials.

[161]  S. Gambhir Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[162]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[163]  Lehui Lu,et al.  Nanoparticulate X-ray computed tomography contrast agents: from design validation to in vivo applications. , 2012, Accounts of chemical research.

[164]  R. J. Lee,et al.  Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.

[165]  A. Boddy,et al.  A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours , 2011, British Journal of Cancer.

[166]  S. Wise Nanocarriers as an emerging platform for cancer therapy , 2007 .